Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Aug;70(2):270–277. doi: 10.1038/bjc.1994.291

Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease.

G Plu-Bureau 1, M G Lê 1, R Sitruk-Ware 1, J C Thalabard 1, P Mauvais-Jarvis 1
PMCID: PMC2033511  PMID: 8054275

Abstract

A cohort study of 1,150 premenopausal French women with benign breast disease diagnosed in two breast clinics between 1976 and 1979 was carried out to analyse the relationship between progestogen use and the risk of breast cancer. The follow-up accumulated 12,462 person-years. The risk of breast cancer was estimated using a Poisson regression analysis on person-time data and the proportional hazards model. In the latter analysis, cumulated progestogen use and age were considered as time-varying covariables and adjustment was performed on the main risk factors for breast cancer. Neither overall progestogen use nor the duration of use was found to be significantly associated with the risk of breast cancer. When progestogens were classified into two categories according to their hormonal potency (19-nortestosterone derivatives vs other progestogens), 19-nortestosterone derivative use was found to be significantly associated with a lower risk of breast cancer. In the adjusted model, the corresponding risk of breast cancer was 0.48 (95% confidence interval 0.25-0.90). In addition, there was a linear trend in the decrease of the relative risk of breast cancer with the duration of use (P = 0.02). These results do not support the hypothesis that progestogens might increase the breast cancer risk. They suggest, instead, that treatment with 19-nortestosterone derivatives might have a beneficial effect on the risk of breast cancer in women with benign breast disease.

Full text

PDF
270

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrat J., Durand Chèné F. Contraception par profestatifs administrés sous forme séquentielle. Nouv Presse Med. 1980 May 10;9(21):1491–1494. [PubMed] [Google Scholar]
  2. Barrat J., de Lignières B., Marpeau L., Larue L., Fournier S., Nahoul K., Linares G., Giorgi H., Contesso G. Effet in vivo de l'administration locale de progestérone sur l'activité mitotique des galactophores humains. Résultat d'une étude pilote. J Gynecol Obstet Biol Reprod (Paris) 1990;19(3):269–274. [PubMed] [Google Scholar]
  3. Bergkvist L., Adami H. O., Persson I., Hoover R., Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med. 1989 Aug 3;321(5):293–297. doi: 10.1056/NEJM198908033210505. [DOI] [PubMed] [Google Scholar]
  4. Bodian C. A. Benign breast diseases, carcinoma in situ, and breast cancer risk. Epidemiol Rev. 1993;15(1):177–187. doi: 10.1093/oxfordjournals.epirev.a036103. [DOI] [PubMed] [Google Scholar]
  5. Brinton L. A., Vessey M. P., Flavel R., Yeates D. Risk factors for benign breast disease. Am J Epidemiol. 1981 Mar;113(3):203–214. doi: 10.1093/oxfordjournals.aje.a113089. [DOI] [PubMed] [Google Scholar]
  6. Bässler R. The morphology of hormone induced structural changes in the female breast. Curr Top Pathol. 1970;53:1–89. doi: 10.1007/978-3-662-30514-0_1. [DOI] [PubMed] [Google Scholar]
  7. Clarke C. L., Sutherland R. L. Progestin regulation of cellular proliferation. Endocr Rev. 1990 May;11(2):266–301. doi: 10.1210/edrv-11-2-266. [DOI] [PubMed] [Google Scholar]
  8. Colditz G. A., Egan K. M., Stampfer M. J. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol. 1993 May;168(5):1473–1480. doi: 10.1016/s0002-9378(11)90784-4. [DOI] [PubMed] [Google Scholar]
  9. Dorflinger L. J. Relative potency of progestins used in oral contraceptives. Contraception. 1985 Jun;31(6):557–570. doi: 10.1016/0010-7824(85)90056-3. [DOI] [PubMed] [Google Scholar]
  10. Dupont W. D., Page D. L. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985 Jan 17;312(3):146–151. doi: 10.1056/NEJM198501173120303. [DOI] [PubMed] [Google Scholar]
  11. Edgren R. A., Sturtevant F. M. Potencies of oral contraceptives. Am J Obstet Gynecol. 1976 Aug 15;125(8):1029–1038. doi: 10.1016/0002-9378(76)90804-8. [DOI] [PubMed] [Google Scholar]
  12. Ernster V. L., Cummings S. R. Progesterone and breast cancer. Obstet Gynecol. 1986 Nov;68(5):715–717. [PubMed] [Google Scholar]
  13. Ewertz M. Oral contraceptives and breast cancer risk in Denmark. Eur J Cancer. 1992;28A(6-7):1176–1181. doi: 10.1016/0959-8049(92)90481-g. [DOI] [PubMed] [Google Scholar]
  14. Ferguson D. J., Anderson T. J. Morphological evaluation of cell turnover in relation to the menstrual cycle in the "resting" human breast. Br J Cancer. 1981 Aug;44(2):177–181. doi: 10.1038/bjc.1981.168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Freedman L. S. Tables of the number of patients required in clinical trials using the logrank test. Stat Med. 1982 Apr-Jun;1(2):121–129. doi: 10.1002/sim.4780010204. [DOI] [PubMed] [Google Scholar]
  16. Fugh-Berman A., Epstein S. Should healthy women take tamoxifen? N Engl J Med. 1992 Nov 26;327(22):1596–1597. doi: 10.1056/NEJM199211263272212. [DOI] [PubMed] [Google Scholar]
  17. Gambrell R. D., Jr, Maier R. C., Sanders B. I. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol. 1983 Oct;62(4):435–443. [PubMed] [Google Scholar]
  18. Gambrell R. D., Jr Role of progestogens in the prevention of breast cancer. Maturitas. 1986 Jul;8(2):169–176. doi: 10.1016/0378-5122(86)90023-x. [DOI] [PubMed] [Google Scholar]
  19. Henderson B. E., Ross R., Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1988 Jan 15;48(2):246–253. [PubMed] [Google Scholar]
  20. Horwitz K. B., Wei L. L., Sedlacek S. M., d'Arville C. N. Progestin action and progesterone receptor structure in human breast cancer: a review. Recent Prog Horm Res. 1985;41:249–316. doi: 10.1016/b978-0-12-571141-8.50010-x. [DOI] [PubMed] [Google Scholar]
  21. Jeng M. H., Parker C. J., Jordan V. C. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res. 1992 Dec 1;52(23):6539–6546. [PubMed] [Google Scholar]
  22. Key T. J., Pike M. C. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol. 1988 Jan;24(1):29–43. doi: 10.1016/0277-5379(88)90173-3. [DOI] [PubMed] [Google Scholar]
  23. Kuttenn F., Fournier S., Durand J. C., Mauvais-Jarvis P. Estradiol and progesterone receptors in human breast fibroadenomas. J Clin Endocrinol Metab. 1981 Jun;52(6):1225–1229. doi: 10.1210/jcem-52-6-1225. [DOI] [PubMed] [Google Scholar]
  24. Kuttenn F., Moufarège A., Mauvais-Jarvis P. Bases hormanles de la contraception progestative discontinue. Nouv Presse Med. 1978 Oct 14;7(35):3109–3113. [PubMed] [Google Scholar]
  25. Lee N. C., Rubin G. L. Breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol. 1984 Dec;64(6):832–834. [PubMed] [Google Scholar]
  26. Lippman M. E., Dickson R. B., Bates S., Knabbe C., Huff K., Swain S., McManaway M., Bronzert D., Kasid A., Gelmann E. P. 8th San Antonio Breast Cancer Symposium--Plenary lecture. Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat. 1986;7(2):59–70. doi: 10.1007/BF01806790. [DOI] [PubMed] [Google Scholar]
  27. Longacre T. A., Bartow S. A. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol. 1986 Jun;10(6):382–393. doi: 10.1097/00000478-198606000-00003. [DOI] [PubMed] [Google Scholar]
  28. Longman S. M., Buehring G. C. Oral contraceptives and breast cancer. In vitro effect of contraceptive steroids on human mammary cell growth. Cancer. 1987 Jan 15;59(2):281–287. doi: 10.1002/1097-0142(19870115)59:2<281::aid-cncr2820590218>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  29. Masters J. R., Drife J. O., Scarisbrick J. J. Cyclic Variation of DNA synthesis in human breast epithelium. J Natl Cancer Inst. 1977 May;58(5):1263–1265. doi: 10.1093/jnci/58.5.1263. [DOI] [PubMed] [Google Scholar]
  30. Maudelonde T., Lavaud P., Salazar G., Laffargue F., Rochefort H. Progestin treatment depresses estrogen receptor but not cathepsin D levels in needle aspirates of benign breast disease. Breast Cancer Res Treat. 1991 Oct;19(2):95–102. doi: 10.1007/BF01980939. [DOI] [PubMed] [Google Scholar]
  31. Mauvais-Jarvis P., Kuttenn F., Gompel A. Antiestrogen action of progesterone in breast tissue. Breast Cancer Res Treat. 1986;8(3):179–188. doi: 10.1007/BF01807330. [DOI] [PubMed] [Google Scholar]
  32. Mauvais-Jarvis P., Sitruk-Ware R., Kuttenn F. Luteal phase defect and breast cancer genesis. Breast Cancer Res Treat. 1982;2(2):139–150. doi: 10.1007/BF01806450. [DOI] [PubMed] [Google Scholar]
  33. McFadyen I. J., Raab G. M., Macintyre C. C., Forrest A. P. Progesterone cream for cyclic breast pain. BMJ. 1989 Apr 8;298(6678):931–931. doi: 10.1136/bmj.298.6678.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Meyer J. S. Cell proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine. Effects of menstrual phase, age, and oral contraceptive hormones. Hum Pathol. 1977 Jan;8(1):67–81. doi: 10.1016/s0046-8177(77)80066-x. [DOI] [PubMed] [Google Scholar]
  35. Miller A. B., Bulbrook R. D. The epidemiology and etiology of breast cancer. N Engl J Med. 1980 Nov 20;303(21):1246–1248. doi: 10.1056/NEJM198011203032130. [DOI] [PubMed] [Google Scholar]
  36. Pearce N., Checkoway H. A simple computer program for generating person-time data in cohort studies involving time-related factors. Am J Epidemiol. 1987 Jun;125(6):1085–1091. doi: 10.1093/oxfordjournals.aje.a114624. [DOI] [PubMed] [Google Scholar]
  37. Persson I., Yuen J., Bergkvist L., Adami H. O., Hoover R., Schairer C. Combined oestrogen-progestogen replacement and breast cancer risk. Lancet. 1992 Oct 24;340(8826):1044–1044. doi: 10.1016/0140-6736(92)93064-t. [DOI] [PubMed] [Google Scholar]
  38. Pike M. C., Henderson B. E., Krailo M. D., Duke A., Roy S. Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet. 1983 Oct 22;2(8356):926–930. doi: 10.1016/s0140-6736(83)90450-6. [DOI] [PubMed] [Google Scholar]
  39. Plu-Bureau G., Thalabard J. C., Sitruk-Ware R., Asselain B., Mauvais-Jarvis P. Cyclical mastalgia as a marker of breast cancer susceptibility: results of a case-control study among French women. Br J Cancer. 1992 Jun;65(6):945–949. doi: 10.1038/bjc.1992.198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Potten C. S., Watson R. J., Williams G. T., Tickle S., Roberts S. A., Harris M., Howell A. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer. 1988 Aug;58(2):163–170. doi: 10.1038/bjc.1988.185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Powles T. J., Hardy J. R., Ashley S. E., Farrington G. M., Cosgrove D., Davey J. B., Dowsett M., McKinna J. A., Nash A. G., Sinnett H. D. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer. 1989 Jul;60(1):126–131. doi: 10.1038/bjc.1989.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Sillero-Arenas M., Delgado-Rodriguez M., Rodigues-Canteras R., Bueno-Cavanillas A., Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol. 1992 Feb;79(2):286–294. [PubMed] [Google Scholar]
  43. Stadel B. V., Rubin G. L., Webster L. A., Schlesselman J. J., Wingo P. A. Oral contraceptives and breast cancer in young women. Lancet. 1985 Nov 2;2(8462):970–973. doi: 10.1016/s0140-6736(85)90524-0. [DOI] [PubMed] [Google Scholar]
  44. Staffa J. A., Newschaffer C. J., Jones J. K., Miller V. Progestins and breast cancer: an epidemiologic review. Fertil Steril. 1992 Mar;57(3):473–491. [PubMed] [Google Scholar]
  45. Stanford J. L., Thomas D. B. Exogenous progestins and breast cancer. Epidemiol Rev. 1993;15(1):98–107. doi: 10.1093/oxfordjournals.epirev.a036120. [DOI] [PubMed] [Google Scholar]
  46. Vogel P. M., Georgiade N. G., Fetter B. F., Vogel F. S., McCarty K. S., Jr The correlation of histologic changes in the human breast with the menstrual cycle. Am J Pathol. 1981 Jul;104(1):23–34. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES